                         SEQUENCE LISTING

<110>  WILLIAMS, John
       DONALDSON, Josh
       HORNE, David
       MA, Yulong
       ZER, Cindy
       BZYMEK, Krzysztof
       AVERY, Kendra
 
<120>  A MONOCLONAL ANTIBODY FRAMEWORK BINDING INTERFACE FOR MEDITOPES, 
       MEDITOPE DELIVERY SYSTEMS AND METHODS FOR THEIR USE

<130>  54435.8081.WO00

<140>  PCT/US11/55656
<141>  2011-10-10

<150>  US 61/391,558
<151>  2010-10-08

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  unmodified cQFD meditope

<400>  1

Cys Gln Phe Asp Leu Ser Thr Arg Arg Leu Lys Cys 
1               5                   10          


<210>  2
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  unmodified cQYN meditope

<400>  2

Cys Gln Tyr Asn Leu Ser Ser Arg Ala Leu Lys Cys 
1               5                   10          


<210>  3
<211>  867
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  meditope-Fc tethering agent

<400>  3
acacccaagc tggctagcga caccatgaag tgtagctggg tcatcttctt tctgatggca       60

gtcgtgacag gagtgaattc gtgccagttt gacctgtcaa ctcggcgact gaaatgcggt      120

gggggctccg gttcaggctc gggcggttca tcgggaggag ggggagggga acctaagtca      180

tgcgataaga cgcacacctg tcctccatgc ccagcccccg agttgcttgg tgggccctca      240

gtattcctct tccctccaaa acccaaagac accttgatga tttcccgcac gccggaagtc      300

acgtgtgtgg tcgtggatgt gagccatgag gatcccgagg tgaagttcaa ttggtacgtg      360

gatggagtag aggtacacaa cgcgaaaacg aagcccaggg aggaacagta caattccaca      420

tatcgcgtgg tgtccgtgct tactgtgttg catcaagact ggctgaatgg gaaggagtat      480

aagtgcaaag tatcaaacaa ggcgctgcct gctccaatcg aaaagaccat ctcgaaggcg      540

aaaggacaac ccagagaacc ccaagtctac acgcttccgc cctcgcggga tgagctcacc      600

aaaaaccagg tatccctcac ttgtttggta aaaggattct acccgtcgga cattgcagtc      660

gagtgggagt cgaatgggca gccggaaaac aactacaaaa caacaccgcc cgtcttggac      720

tccgatggtt cgttctttct ctattcgaag ctcaccgtag acaagtcgag gtggcagcag      780

ggcaacgtct tttcgtgctc agtgatgcat gaggcccttc acaatcacta tacgcagaaa      840

agcctgagcc tgtcaccggg gaagtaa                                          867


<210>  4
<211>  288
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  meditope-Fc tethering agent

<400>  4

Thr Pro Lys Leu Ala Ser Asp Thr Met Lys Cys Ser Trp Val Ile Phe 
1               5                   10                  15      


Phe Leu Met Ala Val Val Thr Gly Val Asn Ser Cys Gln Phe Asp Leu 
            20                  25                  30          


Ser Thr Arg Arg Leu Lys Cys Gly Gly Gly Ser Gly Ser Gly Ser Gly 
        35                  40                  45              


Gly Ser Ser Gly Gly Gly Gly Gly Glu Pro Lys Ser Cys Asp Lys Thr 
    50                  55                  60                  


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
65                  70                  75                  80  


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
                85                  90                  95      


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
            100                 105                 110         


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
        115                 120                 125             


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 
    130                 135                 140                 


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
145                 150                 155                 160 


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
                165                 170                 175     


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
            180                 185                 190         


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 
        195                 200                 205             


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
    210                 215                 220                 


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
225                 230                 235                 240 


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
                245                 250                 255     


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
            260                 265                 270         


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
        275                 280                 285             


<210>  5
<211>  1410
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  meditope-enabled trastuzumab heavy chain

<400>  5
atgaaatgct cgtgggtgat ctttttcctt atggcggtag taaccggagt aaactccgag       60

gtccagctcg tcgaatccgg tggcggcttg gtgcagccgg gtgggtcgtt gcgactgtcg      120

tgcgcagcgt cggggtttaa catcaaagac acctatatcc actgggtgag gcaatcgccc      180

ggaaaggggc tcgaatgggt agccagaatc taccctacga atggttatac tcgatatgcg      240

gactccgtga aaggaagatt caccatcagc gcagatacgt ccaaaaacac tgcatacctc      300

cagatgaata gccttcgggc ggaggacacg gcgatctact actgtagccg gtggggtggg      360

gacgggttct atgcgatgga ctactgggga caggggacgc ttgtaacggt cagctcggcg      420

tcaacaaagg gacctagcgt gtttcccttg gctccctcat cgaaatcaac gtccggtggg      480

acggcggcat tggggtgtct tgtcaaggac tatttccccg agcccgtgac agtctcgtgg      540

aactcgggtg cccttacaag cggcgtacat acgtttcccg ccgtgctcca atcatccgga      600

ctgtattccc tttcatccgt cgtgactgtg ccgtcctcgt cactcggaac gcaaacttac      660

atttgcaatg tcaaccacaa accgtcaaat acaaaggtcg ataagaaggt cgagccaaag      720

tcgtgtgata agacccacac atgccctccc tgtccagcgc cggagctgtt gggagggcct      780

tcagtgttcc tcttcccgcc caaacccaag gacaccctga tgattagccg cacacccgag      840

gtgacgtgtg tcgtcgtcga tgtctcacat gaggacccgg aggtaaagtt caactggtac      900

gtggatggag tcgaagtgca caacgcaaaa acaaaacctc gggaagagca gtacaatagc      960

acgtacagag tagtcagcgt gctcaccgtg ctgcaccagg attggctcaa tggaaaggag     1020

tacaagtgta aagtgtcgaa taaggcgctg cctgccccca tcgaaaagac aatttccaaa     1080

gctaaagggc aaccccgcga gccgcaagta tacaccctcc caccctcgcg cgatgaactg     1140

accaagaacc aggtgtcatt gacgtgtctc gtcaagggct tctatccgag cgacattgca     1200

gtagaatggg aaagcaacgg acagccggaa aacaactaca agactacacc gcctgtcctt     1260

gattcggatg gttccttctt tctttactca aaacttacag tcgacaaatc gaggtggcag     1320

cagggaaatg tgttttcgtg cagcgtgatg cacgaggcct tgcataatca ctatacacag     1380

aagtcgttgt cactgtcgcc gggaaagtaa                                      1410


<210>  6
<211>  180
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  meditope-enabled trastuzumab heavy chain

<400>  6

Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 
1               5                   10                  15      


Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp 
            20                  25                  30          


Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr 
        35                  40                  45              


Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe 
    50                  55                  60                  


Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn 
65                  70                  75                  80  


Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ser Arg Trp Gly 
                85                  90                  95      


Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125             


Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 
    130                 135                 140                 


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
145                 150                 155                 160 


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
                165                 170                 175     


Gly Leu Tyr Ser 
            180 


<210>  7
<211>  180
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  wildtype trastuzumab heavy chain

<400>  7

Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 
1               5                   10                  15      


Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp 
            20                  25                  30          


Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr 
        35                  40                  45              


Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe 
    50                  55                  60                  


Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn 
65                  70                  75                  80  


Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly 
                85                  90                  95      


Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125             


Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 
    130                 135                 140                 


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
145                 150                 155                 160 


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
                165                 170                 175     


Gly Leu Tyr Ser 
            180 


<210>  8
<211>  705
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  meditope-enabled trastuzumab light chain

<400>  8
atggagacag acacgctttt gctttgggtg ttgttgttgt gggtccccgg ttcgacgggg       60

gatattcaga tgacccagtc accgatcctt ctctcggcga gcgtggggga tagagtaacg      120

atcacgtgta gagcgtccca agacgtcaac acagctgtcg cgtggtatca gcagcggaca      180

aatggatcgc cgaggctcct gatctacagc gcatcatttc tctattcggg agtcccctcc      240

cgattttccg gatcgcgcag cggtactgac ttcaccctca cgatttcctc ccttcaaccg      300

gaagatatcg ctgattacta ctgtcagcag cactatacaa cacctcccac tttcggagca      360

gggacaaaag tggagattaa gcgcactgta gcagccccct cggtctttat cttccctcct      420

agcgacgaac aattgaagtc agggaccgcc tcggtggtat gcctgcttaa caacttttac      480

ccacgggaag ccaaagtaca gtggaaggtg gataatgcgc tccagagcgg aaactcccaa      540

gagagcgtga cagaacagga ctcgaaggat tcgacgtact cactcagctc aacgctgacc      600

ctgtcgaaag cggactatga gaaacacaag gtctacgcgt gcgaggtgac ccatcagggc      660

ctgagctccc ccgtaactaa gtcattcaac cggggtgaat gctaa                      705


<210>  9
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  meditope-enabled trastuzumab light chain

<400>  9

Asp Ile Gln Met Thr Gln Ser Pro Ile Leu Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  10
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  wildtype trastuzumab light chain

<400>  10

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  11
<211>  1440
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  meditope-enabled HER2 heavy chain

<400>  11
tcactatagg ggaagcttgc cgccaccatg aaatgctcgt gggtgatctt tttccttatg       60

gcggtagtaa ccggagttaa ctccgaggtc cagctcgtcg aatccggtgg cggcttggtg      120

cagccgggtg ggtcgttgcg actgtcgtgc gcagcgtcgg ggtttaacat caaagacacc      180

tatatccact gggtgaggca agcgcccgga aaggggctcg aatgggtagc cagaatctac      240

cctacgaatg gttatactcg atatgcggac tccgtgaaag gaagattcac catcagcgca      300

gatacgtcca aaaacactgc atacctccag atgaatagcc ttcgggcgga ggacacggcg      360

gtctactact gtagccggtg gggtggggac gggttctatg cgatggacta ctggggacag      420

gggacgcttg taacggtcag ctcggctagc acaaagggac ctagcgtgtt tcccttggct      480

ccctcatcga aatcaacgtc cggtgggacg gcggcattgg ggtgtcttgt caaggactat      540

ttccccgagc ccgtgacagt ctcgtggaac tcgggtgccc ttacaagcgg cgtacatacg      600

tttcccgccg tgctccaatc atccggactg tattcccttt catccgtcgt gactgtgccg      660

tcctcgtcac tcggaacgca aacttacatt tgcaatgtca accacaaacc gtcaaataca      720

aaggtcgata agaaggtcga gccaaagtcg tgtgataaga cccacacatg ccctccctgt      780

ccagcgccgg agctgttggg agggccttca gtgttcctct tcccgcccaa acccaaggac      840

accctgatga ttagccgcac acccgaggtg acgtgtgtcg tcgtcgatgt ctcacatgag      900

gacccggagg taaagttcaa ctggtacgtg gatggagtcg aagtgcacaa cgcaaaaaca      960

aaacctcggg aagagcagta caatagcacg tacagagtag tcagcgtgct caccgtgctg     1020

caccaggatt ggctcaatgg aaaggagtac aagtgtaaag tgtcgaataa ggcgctgcct     1080

gcccccatcg aaaagacaat ttccaaagct aaagggcaac cccgcgagcc gcaagtatac     1140

accctcccac cctcgcgcga tgaactgacc aagaaccagg tgtcattgac gtgtctcgtc     1200

aagggcttct atccgagcga cattgcagta gaatgggaaa gcaacggaca gccggaaaac     1260

aactacaaga ctacaccgcc tgtccttgat tcggatggtt ccttctttct ttactcaaaa     1320

cttacagtcg acaaatcgag gtggcagcag ggaaatgtgt tttcgtgcag cgtgatgcac     1380

gaggccttgc ataatcacta tacacagaag tcgttgtcac tgtcgccggg aaagtaatga     1440


<210>  12
<211>  477
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  meditope-enabled HER2 heavy chain

<400>  12

Ser Leu Gly Lys Leu Ala Ala Thr Met Lys Cys Ser Trp Val Ile Phe 
1               5                   10                  15      


Phe Leu Met Ala Val Val Thr Gly Val Asn Ser Glu Val Gln Leu Val 
            20                  25                  30          


Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser 
        35                  40                  45              


Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val 
    50                  55                  60                  


Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr Pro 
65                  70                  75                  80  


Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr 
                85                  90                  95      


Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser 
            100                 105                 110         


Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly 
        115                 120                 125             


Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 
    130                 135                 140                 


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 
145                 150                 155                 160 


Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 
                165                 170                 175     


Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 
            180                 185                 190         


Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 
        195                 200                 205             


Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 
    210                 215                 220                 


Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 
225                 230                 235                 240 


Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 
                245                 250                 255     


Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 
            260                 265                 270         


Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 
        275                 280                 285             


Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 
    290                 295                 300                 


Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 
305                 310                 315                 320 


Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 
                325                 330                 335     


Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 
            340                 345                 350         


Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 
        355                 360                 365             


Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 
    370                 375                 380                 


Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 
385                 390                 395                 400 


Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 
                405                 410                 415     


Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 
            420                 425                 430         


Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 
        435                 440                 445             


Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 
    450                 455                 460                 


His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
465                 470                 475         


<210>  13
<211>  730
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  meditope-enabled HER2 light chain

<400>  13
ataggggaag cttgccgcca ccatggagac agacacgctt ttgctttggg tgttgttgtt       60

gtgggtcccc ggttcgaccg gtgatattca gatgacccag tcaccgtcat ccctttcggc      120

gagcgtgggg gatagagtaa cgatcacgtg tagagcgtcc caagacgtca acacagctgt      180

cgcgtggtat cagcagaagc caggaaaagc gccgaagctc ctgatctaca gcgcatcatt      240

tctctattcg ggagtcccct cccgattttc cggatcgcgc agcggtactg acttcaccct      300

cacgatttcc tcccttcaac cggaagattt tgctacttac tactgtcagc agcactatac      360

aacacctccc actttcggac aggggacaaa agtggagatt aagcggaccg tagcagcccc      420

ctcggtcttt atcttccctc ctagcgacga acaattgaag tcagggaccg cctcggtggt      480

atgcctgctt aacaactttt acccacggga agccaaagta cagtggaagg tggataatgc      540

gctccagagc ggaaactccc aagagagcgt gacagaacag gactcgaagg attcgacgta      600

ctcactcagc tcaacgctga ccctgtcgaa agcggactat gagaaacaca aggtctacgc      660

gtgcgaggtg acccatcagg gcctgagctc ccccgtaact aagtcattca accggggtga      720

atgctaatga                                                             730


<210>  14
<211>  240
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  meditope-enabled HER2 light chain

<400>  14

Gly Lys Leu Ala Ala Thr Met Glu Thr Asp Thr Leu Leu Leu Trp Val 
1               5                   10                  15      


Leu Leu Leu Trp Val Pro Gly Ser Thr Gly Asp Ile Gln Met Thr Gln 
            20                  25                  30          


Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr 
        35                  40                  45              


Cys Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln 
    50                  55                  60                  


Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu 
65                  70                  75                  80  


Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp 
                85                  90                  95      


Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr 
            100                 105                 110         


Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr 
        115                 120                 125             


Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe 
    130                 135                 140                 


Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys 
145                 150                 155                 160 


Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val 
                165                 170                 175     


Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln 
            180                 185                 190         


Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser 
        195                 200                 205             


Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His 
    210                 215                 220                 


Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
225                 230                 235                 240 


<210>  15
<211>  221
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cetuximab IgG Fab domain

<400>  15

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 
    50                  55                  60                  


Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe 
        115                 120                 125             


Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 
    130                 135                 140                 


Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 
145                 150                 155                 160 


Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 
                165                 170                 175     


Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 
            180                 185                 190         


Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 
        195                 200                 205             


Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 
    210                 215                 220     


<210>  16
<211>  221
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cetuximab IgE Fab domain

<400>  16

Gln Val Ser Leu Arg Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Arg His His 
            20                  25                  30          


Gly Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Ser Leu Ser Gly Ser Gly Thr Lys Thr His Phe Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Asn Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asp Asn Val Arg Asp Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Ala Lys Arg Val Gly Ala Thr Gly Tyr Phe Asp Leu Trp Gly 
            100                 105                 110         


Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Ala Glu Pro 
    210                 215                 220     


